Predictive value of neutrophil to lymphocyte ratio and platelet to lymphocyte ratio in advanced hepatocellular carcinoma patients treated with anti–PD‐1 therapy

Background Currently, there are no recognized or validated biomarkers to identify hepatocellular carcinoma patients (HCC) likely to benefit from anti–PD‐1 therapy. We evaluated the relationship between neutrophil‐lymphocyte ratio (NLR) and platelet‐lymphocyte ratio (PLR) and survival outcomes, pretr...

Full description

Saved in:
Bibliographic Details
Published in:Cancer medicine (Malden, MA) MA), 2020-07, Vol.9 (14), p.4962-4970
Main Authors: Dharmapuri, Sirish, Özbek, Umut, Lin, Jung‐Yi, Sung, Max, Schwartz, Myron, Branch, Andrea D., Ang, Celina
Format: Article
Language:English
Subjects:
Adult
Aged
Aged, 80 and over
Biomarkers
Blood Platelets - metabolism
Carcinoma, Hepatocellular - blood
Carcinoma, Hepatocellular - drug therapy
Clinical Cancer Research
FDA approval
Female
Hepatitis
Hepatocellular carcinoma
Humans
Immune Checkpoint Inhibitors - pharmacology
Immune Checkpoint Inhibitors - therapeutic use
Immunotherapy
Infections
Inflammation
Liver cancer
Liver Neoplasms - blood
Liver Neoplasms - drug therapy
Lymphocytes
Lymphocytes - metabolism
Male
Medical records
Melanoma
Middle Aged
Monoclonal antibodies
Neutrophils
Neutrophils - metabolism
neutrophil‐lymphocyte ratio
NLR
Original Research
Patients
Platelets
platelet‐lymphocyte ratio
PLR
Prognosis
Targeted cancer therapy
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background Currently, there are no recognized or validated biomarkers to identify hepatocellular carcinoma patients (HCC) likely to benefit from anti–PD‐1 therapy. We evaluated the relationship between neutrophil‐lymphocyte ratio (NLR) and platelet‐lymphocyte ratio (PLR) and survival outcomes, pretreatment and after three doses (posttreatment) of nivolumab in HCC patients. Methods Medical records of HCC patients treated with nivolumab between June 2016 and July 2018 were reviewed. Kaplan‐Meier analysis and the log‐rank test were used to calculate and compare overall survival between NLR 
ISSN:2045-7634
2045-7634
DOI:10.1002/cam4.3135